Real-world safety and effectiveness of avelumab in immune-compromised (IC) and non-IC patients with Merkel cell carcinoma (MCC): Results from a prospective German registry (MCC-TRIM)
Jürgen Becker(University of the Western Cape), Selma Ugurel(Klinikum Bielefeld), Claudia Pföhler(Saarland University), Dirk Schadendorf(National Center for Tumor Diseases), Emmanuelle Boutmy(Merck KGaA, Darmstadt (Germany)), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Stephan Grabbe(Goethe University Frankfurt), Fabian Ziller(Vivantes Klinikum), Margarita Shlaen, Lisa Zimmer(The University of Sydney), Katia Ruth(Merck KGaA, Darmstadt (Germany)), Seyed Hamidreza Mahmoudpour(Johannes Gutenberg University Mainz), Dina Oksen(Merck KGaA, Darmstadt (Germany)), Ulrike Leiter(University of Tübingen), Mairead Kearney(Merck KGaA, Darmstadt (Germany)), Rudolf Herbst(Helios Klinikum Erfurt), Sebastian Hoff(Merck KGaA, Darmstadt (Germany)), Christoffer Gebhardt(Universität Hamburg)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k